Related Experiment Videos
[Multiple type I pseudohypoaldosteronism: neonatal management and outcome]
M Cristina De Frutos Martínez1, M Elorza Martínez, S Salas Hernández
1Servicio de Neonatología, Hospital Infantil La Paz, Universidad Autónoma de Madrid. aneumoin@chdo.osakidetza.net
Anales Espanoles De Pediatria
|September 27, 2000
Summary
Multiple type I pseudohypoaldosteronism (PHA-I) is a rare genetic disorder causing severe salt-wasting and hyperkalemia in newborns. Early diagnosis and management are crucial for normal growth and neurodevelopment.
Area of Science:
- Pediatric Endocrinology
- Genetics
- Nephrology
Background:
- Multiple type I pseudohypoaldosteronism (PHA-I) is an autosomal recessive disorder characterized by target-organ unresponsiveness to aldosterone.
- It presents in newborns with severe salt-wasting and hyperkalemia, often leading to dehydration.
Observation:
- Two cases of female infants diagnosed with multiple PHA-I are presented.
- Both infants exhibited dehydration, hyperkalemia, hyponatremia, metabolic acidosis, and elevated plasma renin activity and aldosterone levels.
- One infant had a sibling who died from hyperkalemia in the first week of life.
Findings:
- Diagnosis was based on clinical presentation and confirmed by elevated sweat electrolytes.
- Treatment involved salt and sodium bicarbonate supplements, potassium restriction, cation exchange resins, and fluid management.
- Both patients experienced severe salt-losing crises requiring hospitalization, particularly during the first year of life.
Implications:
- Multiple PHA-I should be suspected in newborns presenting with salt-loss and hyperkalemia, in the absence of glucocorticoid deficiency.
- While initial management requires intensive care and hospitalization, patients often show improvement with age, allowing for ambulatory management after the first year.
- Long-term supplementation and monitoring are necessary to ensure normal growth and neurodevelopment.